Aurothiomalate

Aurothiomalate is a parentally administered preparation of Gold. Gold compounds were introduced for the treatment of rheumatoid arthritis in the 1920s. Aurothiomalate is administered intramuscularly as water soluble gold salt containing 50 % elemental gold. Gold therapy is indicated for active rheumatoid arthritis.

Aurothiomalate is primarily indicated in conditions like Juvenile chronic arthritis, Palindromic rheumatism, Psoriatic arthritis, Rheumatoid arthritis.

Aurothiomalate is contraindicated in conditions like Bone marrow suppression, Nephritis, Pulmonary fibrosis, Hematologic disorders.

The severe or irreversible adverse effects of Aurothiomalate, which give rise to further complications include Renal damage, Thrombocytopenia, Musculoskeletal effects.Aurothiomalate produces potentially life-threatening effects which include Bone marrow aplasia, Neutropenia, Pancytopenia. which are responsible for the discontinuation of Aurothiomalate therapy.The signs and symptoms that are produced after the acute over dosage of Aurothiomalate include Nausea, Vomiting, Erythematous rash, Exfoliative dermatitis, Stomatitis, Pharyngitis, Tracheitis, Gastritis, Colitis, Vaginitis, Blood's dyscrasias, Albuminuria, Hematuria, Acute renal failure, Encephalitis, Polyneuropathy, Jaundice.The symptomatic adverse reactions produced by Aurothiomalate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Mouth ulcers, Skin Rash.

Concerns related to adverse effects: • Dermatologic reactions: Dermatitis and lesions of the mucous membranes are common and may be serious; pruritus may precede the early development of a skin reaction. Consider alternative therapy in patients with dermatitis; may increase risk and/or symptoms of gold toxicity may be more difficult to detect. Use is contraindicated in patients with significant dermatitis, including urticaria or eczema. • GI effects: Signs of toxicity include persistent diarrhea, stomatitis, and enterocolitis; avoid use in patients with prior inflammatory bowel disease. • Hematologic effects: Signs of toxicity include hematologic depression (depressed hemoglobin, eosinophilia, leukocytes, granulocytes, or platelets). Use is contraindicated in patients with a history of blood dyscrasias or a history of agranulocytosis, hemorrhagic diathesis, or drug-induced granulocytopenia or anemia. Symptoms of gold toxicity may be difficult to detect in patients with prior abnormalities; consider alternative therapy. • Hepatic effects: May be associated with the development of cholestatic jaundice. Use is contraindicated in patients with hepatic impairment. • Hypersensitivity reactions: Rare hypersensitivity reactions, including anaphylactic shock, syncope, bradycardia, thickening of the tongue, difficulty in swallowing and breathing, and angioedema have been reported in association with injections of sodium aurothiomalate; treatment should be discontinued if these reactions occur. In addition, a vasomotor (nitritoid) reaction characterized by acute flushing and tachycardia may occur within minutes of injection; this reaction should be differentiated from anaphylaxis and therapy may be continued, but a careful evaluation of risk versus benefit should be undertaken and extreme caution should be exercised before resuming therapy, particularly in patients with cardiovascular disease. • Pulmonary toxicity: May be associated with interstitial fibrosis; monitor closely. • Renal effects: Renal toxicity ranges from mild proteinuria to nephrotic syndrome. Use is contraindicated in patients with renal disease. Disease-related concerns: • Cardiovascular disease: Use caution in patients with heart failure, hypertension, or cerebrovascular disease. Other warnings/precautions: • Administration: Must not be injected IV. • Experienced physician: Physicians should be experienced with chrysotherapy and should be familiar with the toxicity and benefits of therapy. • Monitoring: Frequent monitoring of patients for signs and symptoms of toxicity will prevent serious adverse reactions.

Concerns related to adverse effects: • Dermatologic reactions: Dermatitis and lesions of the mucous membranes are common and may be serious; pruritus may precede the early development of a skin reaction. Consider alternative therapy in patients with dermatitis; may increase risk and/or symptoms of gold toxicity may be more difficult to detect. Use is contraindicated in patients with significant dermatitis, including urticaria or eczema. • GI effects: Signs of toxicity include persistent diarrhea, stomatitis, and enterocolitis; avoid use in patients with prior inflammatory bowel disease. • Hematologic effects: Signs of toxicity include hematologic depression (depressed hemoglobin, eosinophilia, leukocytes, granulocytes, or platelets). Use is contraindicated in patients with a history of blood dyscrasias or a history of agranulocytosis, hemorrhagic diathesis, or drug-induced granulocytopenia or anemia. Symptoms of gold toxicity may be difficult to detect in patients with prior abnormalities; consider alternative therapy. • Hepatic effects: May be associated with the development of cholestatic jaundice. Use is contraindicated in patients with hepatic impairment. • Hypersensitivity reactions: Rare hypersensitivity reactions, including anaphylactic shock, syncope, bradycardia, thickening of the tongue, difficulty in swallowing and breathing, and angioedema have been reported in association with injections of sodium aurothiomalate; treatment should be discontinued if these reactions occur. In addition, a vasomotor (nitritoid) reaction characterized by acute flushing and tachycardia may occur within minutes of injection; this reaction should be differentiated from anaphylaxis and therapy may be continued, but a careful evaluation of risk versus benefit should be undertaken and extreme caution should be exercised before resuming therapy, particularly in patients with cardiovascular disease. • Pulmonary toxicity: May be associated with interstitial fibrosis; monitor closely. • Renal effects: Renal toxicity ranges from mild proteinuria to nephrotic syndrome. Use is contraindicated in patients with renal disease. Disease-related concerns: • Cardiovascular disease: Use caution in patients with heart failure, hypertension, or cerebrovascular disease. Other warnings/precautions: • Administration: Must not be injected IV. • Experienced physician: Physicians should be experienced with chrysotherapy and should be familiar with the toxicity and benefits of therapy. • Monitoring: Frequent monitoring of patients for signs and symptoms of toxicity will prevent serious adverse reactions.

0.085 to 0.128 mg/kg (0.11 (0.1065)) 24 hourly PO — Gradually Increased over 3 Months 0.714 mg/kg (0.71 (0.714)) As recommended. IM — Once in a Week, For 5 Months

0.25 to 0.5 mg/kg (0.38 (0.375)) As recommended. Intra Muscular — Initial, gradually increased 1 mg/kg (1 (1)) As recommended. Intra Muscular — Maintenance per week for 6-8 Months

No neonatal dosage information is recorded for this medicine yet.

Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated. Monitor therapy Aspirin: May enhance the adverse/toxic effect of Gold Sodium Thiomalate. Specifically, liver function tests may be elevated when these agents are combined. Monitor therapy PenicillAMINE: Gold Sodium Thiomalate may enhance the adverse/toxic effect of PenicillAMINE. Specifically, this combination may increase the risk for serious hematologic and/or renal adverse reactions. Avoid combination Phenylbutazone: May enhance the adverse/toxic effect of Gold Sodium Thiomalate. Specifically, the risk for hematologic adverse effects may be increased. Monitor therapy

Inj Protect from Sunlight.